PUBLIC COMPANY
savepharmaand GmbH
updated 2mo ago
community read0 votes
pipeline
3
marketed
2
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
2Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
- phase3A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
- phase2Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
- phase3CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
- phase2A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
- phase2A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
- phase1Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
- —A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that